Heartflow, Inc. (NASDAQ:HTFL) Short Interest Update

Heartflow, Inc. (NASDAQ:HTFL) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 4,951,283 shares, a growth of 42.4% from the January 15th total of 3,476,809 shares. Currently, 5.8% of the shares of the stock are sold short. Based on an average trading volume of 843,019 shares, the short-interest ratio is currently 5.9 days. Based on an average trading volume of 843,019 shares, the short-interest ratio is currently 5.9 days. Currently, 5.8% of the shares of the stock are sold short.

Insider Transactions at Heartflow

In other Heartflow news, Director Julie A. Cullivan sold 8,000 shares of Heartflow stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $27.32, for a total transaction of $218,560.00. Following the sale, the director owned 36,413 shares of the company’s stock, valued at $994,803.16. The trade was a 18.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total transaction of $619,552.52. Following the sale, the chief executive officer directly owned 591,656 shares of the company’s stock, valued at $16,246,873.76. The trade was a 3.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,030,562 shares of company stock valued at $56,938,113 over the last ninety days.

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently made changes to their positions in HTFL. Baillie Gifford & Co. purchased a new stake in Heartflow during the third quarter worth about $101,182,000. New York State Common Retirement Fund purchased a new position in shares of Heartflow in the third quarter valued at approximately $4,015,000. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Heartflow in the third quarter valued at approximately $4,418,000. Board of Trustees of The Leland Stanford Junior University purchased a new stake in Heartflow during the 3rd quarter worth approximately $10,510,000. Finally, Lisanti Capital Growth LLC purchased a new stake in Heartflow during the 3rd quarter worth approximately $982,000.

Analyst Ratings Changes

HTFL has been the topic of several recent research reports. Wells Fargo & Company assumed coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Canaccord Genuity Group lifted their price target on Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Stifel Nicolaus boosted their price target on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Heartflow Price Performance

NASDAQ:HTFL opened at $20.66 on Friday. Heartflow has a 52 week low of $20.13 and a 52 week high of $41.22. The company has a fifty day simple moving average of $29.97. The stock has a market capitalization of $1.76 billion and a P/E ratio of -11.41.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.